Jordan Kadish

Conference Coverage
Sacituzumab Govitecan Improved Response Rate Among Platinum-Ineligible Patients With Urothelial Carcinoma
02/21/2023
According to results presented at the 2023 ASCO GU Cancers Symposium, sacituzumab govitecan monotherapy resulted in heightened response rates among platinum-ineligible patients with metastatic urothelial carcinoma who progressed following...
According to results presented at the 2023 ASCO GU Cancers Symposium, sacituzumab govitecan monotherapy resulted in heightened response rates among platinum-ineligible patients with metastatic urothelial carcinoma who progressed following...
According to results presented...
02/21/2023
Oncology
News
Survival Rates of Histological Transformation in Patients With Follicular Lymphoma
04/04/2023
The phase 3 GALLIUM trial results indicate histological transformation in advance-stage follicular lymphoma was associated with poor overall survival rates.
The phase 3 GALLIUM trial results indicate histological transformation in advance-stage follicular lymphoma was associated with poor overall survival rates.
The phase 3 GALLIUM trial...
04/04/2023
Oncology
News
SNPs as Predictive Biomarkers of Lenalidomide Efficacy Among Patients With Mantle Cell Lymphoma
07/14/2023
A phase 3 trial indicated that certain single nucleotide polymorphisms (SNPs) represent predictive biomarkers associated with lenalidomide efficacy as well as toxicity among patients with mantle cell lymphoma.
A phase 3 trial indicated that certain single nucleotide polymorphisms (SNPs) represent predictive biomarkers associated with lenalidomide efficacy as well as toxicity among patients with mantle cell lymphoma.
A phase 3 trial indicated that...
07/14/2023
Oncology
News
G-CSF Plus Decitabine and Busulfan-Cyclophosphamide Conditioning for Patients With MDS-RAEB and Secondary AML Evolving From MDS
05/11/2023
According to a phase 3 trial, a granulocyte-colony stimulating factor plus decitabine and busulfan-cyclophosphamide conditioning regimen reduced the incidence of relapse among patients with MDS refractory anemia with excess blasts and...
According to a phase 3 trial, a granulocyte-colony stimulating factor plus decitabine and busulfan-cyclophosphamide conditioning regimen reduced the incidence of relapse among patients with MDS refractory anemia with excess blasts and...
According to a phase 3 trial, a...
05/11/2023
Oncology
News
Molecular Scoring System IPSS-M Demonstrates Superior Predictive Potential for Survival and AML Transformation Among Patients With MDS
10/30/2023
Molecular scoring system IPSS-M demonstrated superior accuracy in predicting survival outcomes and acute myeloid leukemia transformation compared to IPSS-R among patients with myelodysplastic syndrome.
Molecular scoring system IPSS-M demonstrated superior accuracy in predicting survival outcomes and acute myeloid leukemia transformation compared to IPSS-R among patients with myelodysplastic syndrome.
Molecular scoring system IPSS-M...
10/30/2023
Oncology
News
Ropeginterferon Alfa-2B Demonstrates Efficacy Among High-Risk Patients With Philadelphia-Negative Myeloproliferative Neoplasms
01/22/2024
A retrospective observational study showed that ropeginterferon alfa-2b demonstrated efficacy among high-risk patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
A retrospective observational study showed that ropeginterferon alfa-2b demonstrated efficacy among high-risk patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
A retrospective observational...
01/22/2024
Oncology
News
Low-Intensity Regimens for Sickle Cell Disease Transplantation Associated With Risk of Secondary Neoplasms
03/13/2023
Low-intensity regimens for sickle cell disease transplantations were associated with a higher risk of secondary neoplasms, including leukemia and myelodysplastic syndromes.
Low-intensity regimens for sickle cell disease transplantations were associated with a higher risk of secondary neoplasms, including leukemia and myelodysplastic syndromes.
Low-intensity regimens for...
03/13/2023
Oncology
News
Asciminib Demonstrated Superior Efficacy and Safety Compared to Bosutinib Among Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
06/23/2023
Results from the ASCEMBL trial indicated that asciminib, a BCR::ABL1 inhibitor, demonstrated superior efficacy and safety compared to bosutinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Results from the ASCEMBL trial indicated that asciminib, a BCR::ABL1 inhibitor, demonstrated superior efficacy and safety compared to bosutinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Results from the ASCEMBL trial...
06/23/2023
Oncology
News
Sequential Bendamustine and Rituximab Plus Cytarabine and Rituximab Regimen With or Without Acalabrutinib Shows Promise for Patients With MCL
08/08/2023
Induction regimens incorporating sequential rather than alternating bendamustine and rituximab plus cytarabine and rituximab sequentially demonstrated promising results among patients with mantle cell lymphoma, according to pooled data from 2...
Induction regimens incorporating sequential rather than alternating bendamustine and rituximab plus cytarabine and rituximab sequentially demonstrated promising results among patients with mantle cell lymphoma, according to pooled data from 2...
Induction regimens incorporating...
08/08/2023
Oncology
News
Obinutuzumab, Ibrutinib, and Venetoclax Combination Demonstrates Sustained Remissions Among Patients With High-Risk CLL
11/03/2023
A regimen consisting of obinutuzumab, ibrutinib, and venetoclax demonstrated promising sustained remission among patients with high-risk chronic lymphocytic leukemia with del(17p) and/or TP53 mutation, according to a final analysis of the...
A regimen consisting of obinutuzumab, ibrutinib, and venetoclax demonstrated promising sustained remission among patients with high-risk chronic lymphocytic leukemia with del(17p) and/or TP53 mutation, according to a final analysis of the...
A regimen consisting of...
11/03/2023
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
LLM Winter Symposium
February 7 ⁠–⁠ February 9
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
GD Solid Tumors
March 22 ⁠–⁠ March 23
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 4
WoundCon
May 1 ⁠–⁠ May 3
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use